Novo Nordisk shares fell about 8% in both Copenhagen and New York on Monday, September 21, 2026, the day of its London Capital Markets Day, according to GEN. BMO Capital Markets analyst Evan Seigerman wrote that Novo is "targeting 2026-2030 revenue growth in line with industry peers, likely underwhelming for investors," and noted that consensus already models about 3.53% annual growth for Novo against roughly 3.65% for pharma peers, so the target appeared priced into Wall Street estimates. The company used the event to set 2030 ambitions that included more than five potential blockbuster launches.
Novo Nordisk set out its 2030 ambitions at its Capital Markets Day in London on Monday, September 21, 2026: launch more than five multi-blockbusters, run at least five Phase 3 programs in obesity and diabetes and at least five in other therapy areas, serve more than 60 million patients, build capacity to serve 10 times more people with obesity on oral GLP-1, keep a broadly stable operating margin, and deliver 2026-2030 revenue growth in line with industry peers. It also targets more than DKK 150 billion (about $23 billion) in pipeline sales in 2035, and it said the ambitions are not financial guidance. Shares fell as much as 9% and were down 4.7% by 11:24 GMT, BNN Bloomberg reported, as management faced questions on pricing and dealmaking. Management said CagriSema would launch early next year, followed by standalone cagrilintide and high-dose CagriSema in 2028, with zenagamtide planned to launch in oral and injectable forms at the same time; BNN Bloomberg also reported a plan to scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by the end of the decade.
Novo Nordisk announced on Thursday, September 17, 2026 that the EMA's CHMP recommended marketing authorization for FREHEMGO (denecimig) to treat hemophilia A, with or without inhibitors, in adults and children. Denecimig is a factor VIIIa-mimetic bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of activated factor VIII. Novo says it is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks, and once-weekly prophylaxis in a single-use pre-filled pen. The application was based on the FRONTIER2, FRONTIER3, and FRONTIER4 trials, and FRONTIER5 showed no new safety signals in patients switching from emicizumab. Pending a European Commission decision, Novo expects launches in the first European countries in Q4 2026 and across the EU starting early 2027.
Orbis Medicines, based in Copenhagen and Lausanne, announced on Thursday, September 17, 2026 a multi-target discovery and license agreement with Novo to design oral macrocycle drugs for undisclosed cardiometabolic targets. Orbis can receive up to $1.4 billion in upfront and development and commercial milestone payments plus tiered royalties, and Novo will make a strategic investment of undisclosed size. The work uses Orbis's nGen platform, which combines generative AI, high-throughput synthesis, and a multi-parameter optimization engine trained on the company's experimental macrocycle data. Orbis chief executive Morten Graugaard said its synthetic macrocycles have reached up to 18% oral bioavailability in preclinical studies. Orbis launched in January 2025 with a €90 million (about $93 million) Series A led by NEA, with Lilly Ventures, Forbion, and Novo Holdings among its investors.
Novo will hold its Capital Markets Day in London on Monday, September 21, 2026, with CEO Mike Doustdar presenting the corporate strategy. A TIKR preview published September 10 noted that the U.S.-listed shares closed at $44.56 on September 9, nearer their 12-month low of $35.12 than their high of $64.16. The preview put total Wegovy pill prescriptions past five million, with the latest million added in four weeks, and the pill's share of the U.S. oral obesity market at about 90%. It also pointed to a U.S. obesity decision on CagriSema at the end of 2026 and to semaglutide losing exclusivity in markets such as Canada and Brazil in the second half of 2026. The event follows Novo's announcement that it will drop 'Nordisk' from its name in day-to-day use.